Co-Authors
This is a "connection" page, showing publications co-authored by RAJENDER APARASU and J. THORNTON.
Connection Strength
1.829
-
Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer. J Manag Care Spec Pharm. 2026 Aug; 32(8):979-993.
Score: 0.249
-
Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. Sci Rep. 2026 Apr 04; 16(1).
Score: 0.243
-
Pain severity and opioid use in patients with spine-related diagnoses. Front Pain Res (Lausanne). 2025; 6:1703201.
Score: 0.239
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.222
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
Score: 0.210
-
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Explor Res Clin Soc Pharm. 2021 Jun; 2:100021.
Score: 0.173
-
Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Prefer Adherence. 2020; 14:2187-2199.
Score: 0.167
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.163
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.162